International journal of clinical pharmacology and therapeutics · 2025
Empagliflozin and hydralazine-isosorbide dinitrate combination therapy improves outcomes in Black patients with heart failure.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Baskaran Padmamalini, Aldhaeefi Mohammed, Asaadi Anahita, Jones Morgan, King Emmanuel, Rungkitwattanakul Dhakrit, Wingate La'Marcus
Аннотация
BACKGROUND: Black patients experience a disproportionately high incidence of heart failure with reduced ejection fraction (HFrEF), where vasodilators serve as a key therapeutic strategy.
MATERIALS AND METHODS: A retrospective cohort study based on medical records of Black patients with HFrEF and an ex vivo analysis of mouse thoracic aorta stimulated with empagliflozin (empa) and hydralazine-isosorbide dinitrate (H-ISDN).
RESULTS: The combination synergistically activated cyclic guanosine monophosphate (cGMP) production in the ex vivo thoracic aorta and improved kidney function, reduced brain natriuretic peptide (BNP), and lowered mortality compared to H-ISDN alone in HFrEF patients.
CONCLUSION: Empa + H-ISDN offered superior benefits in Black patients with HFrEF, possibly by reducing oxidative stress and enhancing nitric oxide (NO) bioavailability.
MATERIALS AND METHODS: A retrospective cohort study based on medical records of Black patients with HFrEF and an ex vivo analysis of mouse thoracic aorta stimulated with empagliflozin (empa) and hydralazine-isosorbide dinitrate (H-ISDN).
RESULTS: The combination synergistically activated cyclic guanosine monophosphate (cGMP) production in the ex vivo thoracic aorta and improved kidney function, reduced brain natriuretic peptide (BNP), and lowered mortality compared to H-ISDN alone in HFrEF patients.
CONCLUSION: Empa + H-ISDN offered superior benefits in Black patients with HFrEF, possibly by reducing oxidative stress and enhancing nitric oxide (NO) bioavailability.
Предметные рубрики MeSH
AgedAnimalsFemaleHumansMaleMiceMiddle AgedBenzhydryl CompoundsBlack or African AmericanCyclic GMPDrug CombinationsGlucosidesHeart FailureHydralazineIsosorbide DinitrateNatriuretic Peptide, BrainNitric OxideOxidative StressRetrospective StudiesSodium-Glucose Transporter 2 InhibitorsStroke VolumeTreatment OutcomeVasodilator Agents